Interim report, foreign filer
Open the filing on sec.gov
OKYO Pharma Limited (OKYO)
Nasdaq: OKYO · Biological Products, (No Diagnostic Substances) · London, GB · filing with the SEC since 2021
The companyfiscal 2025, as filed
Revenuen/a
Net income-$4.7M+72.0%
Earnings per share$-0.20+64.9%
Operating cash flow-$1.8M+80.9%
Cash$1.6M+88.8%
Debtn/a
Shareholders’ equity-$5.5M+5.6%
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202681
Newest filingNov 12 · 6-K
Annual reportJul 20, 2026
Quarterly reportn/a
Next report due20-F by Jul 29
Insider sales, 12 months$0.00
Insider buys, 12 months$100,000
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Annual report, foreign filer, amended
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.